Arginase Enzyme in Iraqi Acromegaly Patients: Biochemical Insights

Malek, Fatima Kh.; Abbas, Salma A.; Abed, Baydaa A.

ISBN 10: 6207461800 / ISBN 13: 9786207461806

Edité par LAP LAMBERT Academic Publishing, 2024

A propos de cet article

N° de réf. du vendeur 26401036911

Détails bibliographiques

• Titre: Arginase Enzyme in Iraqi Acromegaly Patients: Biochemical Insights
• Éditeur: LAP LAMBERT Academic Publishing
• Date de parution: 2024
• Langue: anglais
• ISBN à 10 chiffres: 6207461800
• ISBN à 13 chiffres: 9786207461806
• Reliure: Couverture souple
• État de l'article: New

A propos de ce titre

Synopsis

L-arginase (EC 3.5.3.1), the final enzyme in the urea cycle, is a binuclear Mn2+ metalloenzyme. The enzyme catalyzes a reaction involving the hydrolysis of L-arginine to L-ornithine and urea. Acromegaly (ACRO) is a rare and complex hormonal syndrome classified as a chronic disorder characterized by elevated growth hormone (GH) and, consequently, insulin-like growth factor-1 (IGF-1). This is commonly caused by a GH-secreting pituitary adenoma, leading to multisystem impacts. These impacts affect the osteoarticular system, muscles, brain, heart and blood vessels, respiratory and hematopoietic system, kidneys, liver and pancreas, thyroid, adipose tissue, and metabolic system. The objective of this study is to evaluate the levels of arginase activity, GH, IGF-1, glucose, lipid profile, and serum urea in ACRO patients with and without diabetes. Additionally, the study aims to explore the correlation between Arginase and GH, glucose, and lipid profile.